Nanobiotix and Johnson & Johnson presented early Phase 2 trial data for JNJ-1900 (NBTXR3), a novel nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer (NSCLC). The treatment, combined with chemoradiotherapy and durvalumab, showed an overall response rate of 85.7% and a complete response rate of 57.1% in seven patients, significantly higher than current standards. The therapy was safe and showed potential for durable disease control. These promising results support further development of JNJ-1900 across solid tumors treated with radiotherapy.
A 66-year-old retiree in Pennsylvania aimed to generate $55,000 annually from a $1.1 million portfolio but lost $2,400 in tax savings because her IRA automatically reinvested dividends shortly after she sold shares at a loss. This triggered the IRS w...
The healthcare sector, particularly healthcare equipment, is currently undervalued compared to historical averages. The iShares U.S. Pharmaceuticals ETF (IHE) has notably outperformed the broader healthcare ETF XLV by 27% over the past year, driven l...
A global survey of 817 bladder cancer patients and 802 urologists reveals that standard treatments like bladder removal surgery and BCG therapy significantly harm patients' physical, emotional, and mental health. Over 90% of patients report negative ...
Jill Winther received the 2026 Extraordinary Healer® award at the ONS Congress for her leadership, mentorship, and advocacy in oncology nursing. The award recognizes her dedication to advancing oncology nursing practice and patient-centered care. Sup...
